very interesting as unterschidlich react stakeholders?
The DMSG, Federation reacts with (09.12.09):
"Zamboni [...] study results are ... ... worthless."
He calls this statement also "scientific [s] sentence."
United States and other countries are responding enthusiastically, however, and large-scale studies.
See, eg, Canada, and this:
http://watch.ctv.ca/news/w5/the-liberation-treatment/
Or Boston with 1600 participants, Jena, Germany, Poland, England (London), Italy. Nevertheless, the
DMSG says the study (even in the same article, starting to) "is certainly very interesting findings of Zamboni," while later, "study results are ... ... worthless."
Anyway. You have to decide.
The side effects are essentially zero (no drugs, venous flow is produced, which is always good).
There is no reason to delay treatment longer.
Perhaps one is to (hopefully) agree in this country to be for large studies. In any event, the DMSG not (at least in this article), objected studies. that means that you would promote Soche?
BTW. Consider always that an MS patient, the health insurance costs about 25,000 € a year .... several billion worldwide.
How far reaches of the little finger of the arm or pharmaceutical?
http://www.amsel.de/multiple-sklerose-news/index.php?kategorie=medizin&anr=3440
0 comments:
Post a Comment